Eledon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-36.18	-116.54	-87.97	-34.51	-22.81	Upgrade
Depreciation & Amortization	0.36	0.37	0.37	0.2	0.18	Upgrade
Asset Writedown & Restructuring Costs	-	-	48.65	-	-	Upgrade
Loss (Gain) From Sale of Investments	-2.8	-1.2	-	-	-	Upgrade
Stock-Based Compensation	13.12	6.55	8.15	7.9	3.17	Upgrade
Other Operating Activities	-30.48	76.21	-	-2.35	4.43	Upgrade
Change in Accounts Payable	7.75	-2.6	2.08	2.14	-0.04	Upgrade
Change in Other Net Operating Assets	0.96	-2.32	0.29	-2.3	-0.14	Upgrade
Operating Cash Flow	-47.27	-39.53	-28.42	-28.91	-15.21	Upgrade
Cash Acquisitions	-	-	-	-	11.04	Upgrade
Investment in Securities	-70.31	-45.29	-	-	-	Upgrade
Investing Cash Flow	-70.31	-45.29	-	-	11.04	Upgrade
Issuance of Common Stock	133.52	33.02	-	0	14.38	Upgrade
Repurchase of Common Stock	-	-	-	-	-0.03	Upgrade
Other Financing Activities	-	-	-	-0.45	-	Upgrade
Financing Cash Flow	133.52	33.02	-	-0.45	109.58	Upgrade
Net Cash Flow	15.94	-51.8	-28.42	-29.36	105.4	Upgrade
Free Cash Flow	-47.27	-39.53	-28.42	-28.91	-15.21	Upgrade
Free Cash Flow Per Share	-0.97	-1.61	-1.99	-1.95	-10.48	Upgrade
Levered Free Cash Flow	-21.4	-24.47	-13.85	-15.33	-4.01	Upgrade
Unlevered Free Cash Flow	-21.4	-24.47	-13.85	-15.33	-4.01	Upgrade
Change in Net Working Capital	-9.23	4.52	-2.48	0.39	-0.94	Upgrade

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q